Compare · ABT vs SCTL
ABT vs SCTL
Side-by-side comparison of Abbott Laboratories (ABT) and Societal CDMO Inc. (SCTL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SCTL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $155.32B.
- ABT has hit the wire 6 times in the past 4 weeks while SCTL has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 0 for SCTL).
- Company
- Abbott Laboratories
- Societal CDMO Inc.
- Price
- $89.54+0.49%
- $1.09+0.46%
- Market cap
- $155.32B
- -
- 1M return
- +6.16%
- -
- 1Y return
- -33.68%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Societal CDMO Inc.
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest SCTL
- SEC Form 15-12G filed by Societal CDMO Inc.
- SEC Form EFFECT filed by Societal CDMO Inc.
- SEC Form EFFECT filed by Societal CDMO Inc.
- SEC Form EFFECT filed by Societal CDMO Inc.
- SEC Form SC 13D/A filed by Societal CDMO Inc. (Amendment)
- Arens Mathew Paul closing all direct ownership in the company (SEC Form 4)
- Weisman Wayne returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)
- Reasons Bryan M. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)
- Parks Laura L. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)
- Miller James Charles returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)